Pharma Focus Asia

Takeda and Arrowhead collaborate on joint development and commercialization of ARO-AAT, a candidate for the treatment of α-1 antitrypsin-related liver disease

Tuesday, October 13, 2020

Takeda Pharmaceutical Company Limited and Arrowhead Pharmaceuticals collaborates and licenses ARO-AAT, a candidate for RNA interference (RNAi) treatment, in the development phase of a Phase 2 trial to treat α-1 antitrypsin-related liver disease (AATLD). Announced the contract. ARO-AAT is a first-in-class therapeutic candidate designed to reduce the production of mutant α-1 antitrypsin protein that causes the progression of AATLD.

In accordance with the terms of the agreement, Takeda and Arrowhead will jointly develop ARO-AAT, and if pomalidomide is approved, the two companies will jointly market the drug in the United States in a 50:50 ratio. Outside the United States, Takeda leads a global sales strategy to acquire exclusive rights to commercialize ARO-AAT, and Arrowhead receives a gradual royalty of 20-25% of sales. Get the right to. Arrowhead will receive a $ 300 million down payment and will be entitled to up to $ 740 million in development, regulatory and sales milestone payments. Completion of the transaction is subject to the completion of an antitrust review, including the US 1976 Heart Scott Rodino (HSR) Antitrust Act.

Asit Parikh (MD, Ph.D.), head of Takeda's Gastroenterology Therapeutic Area Unit, said: "AAT-related liver disease is a serious disease for which there is no approved drug. With an RNAi-based mechanism of action, ARO-AAT treats the underlying cause of AATLD so that patients can undergo liver transplantation and association. May help avoid comorbidities. As part of our ever-expanding gastrointestinal portfolio in collaboration with Arrowhead, a great asset for end-stage liver disease for the α-1 disease community. It is a great pleasure for us to move forward. "

Dr. Christopher Anzalone, President and CEO of Arrowhead, said: "Takeda has an international presence in the areas of rare and gastrointestinal disorders, experience with payers and regulators, and a long track record of contributing to the α-1 disease community, leading to ARO-AAT. It is an ideal partner for alliances, and the company is in an advantageous position to work with patients and the medical community to meet the serious unmet needs of patients with α-1 liver disease. The agreement states that we will continue to invest in our Targeted RNAi Molecule (TRiM TM ) platform and our expanding pipeline of RNAi therapeutics targeting diverse tissue types with a selection of partners. At the same time, it underpins our strategy of focusing our sales organizations on opportunities in two key areas: metabolic cardiovascular disease and lung disease. "

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024